News Updates
Scope

Tue, May 12, 2026

1 updates
IRON
9:30 AM

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress

Oral presentation of data from RALLY-MF phase 2 trial of DISC-0974 in patients with myelofibrosis and anemia Additional abstracts highlighting updates on HELIOS open label extension study of bitopertin in EPP, EPP LIGHT study (patient survey on life and health impact of disease), and DISC-3405

Presentation / Abstract • Phase 2EHA oral presentation Fri, Jun 12, 2026, 5:15 PM CESTdiscmedicine.com

Mon, May 11, 2026

1 updates
IRON
8:30 AM

Disc Medicine to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company

discmedicine.com

Tue, May 5, 2026

1 updates

Tue, Apr 21, 2026

1 updates
IRON
10:00 AM

Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual Meeting

WATERTOWN, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it will

Presentation / Abstract • Phase 2discmedicine.com

Thu, Mar 26, 2026

1 updates